Literature DB >> 2788951

Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay.

H Kanamaru1, O Yoshida.   

Abstract

Lymphokine activated killer (LAK) cell activity against renal cancer cell lines was assessed in vitro using a crystal violet assay. A standard 4-h 51chromium release assay and a 48-h crystal violet assay showed that both natural killer-susceptible (NC65) and -resistant (ACHN) renal cancer cell lines were sensitive to LAK cells which had been generated by a 3-day incubation of peripheral blood mononuclear cells (PBMC) with recombinant interleukin 2 (rIL-2). Optimal LAK activity was generated by a 5-day culture of PBMC with 1 U rIL-2/ml. LAK activity was enhanced by the presence of IL-2 in the crystal violet assay system, while it was suppressed by fresh autologous serum. The suppressive effect was found in serum from both normal donors and patients with metastatic renal cell carcinoma, suggesting that non-specific suppressive factor(s) affecting LAK cell activity were present in human sera.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788951     DOI: 10.1007/bf00262607

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  21 in total

1.  Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell.

Authors:  H J Wanebo; T Riley; D Katz; R C Pace; M E Johns; R W Cantrell
Journal:  Cancer       Date:  1988-02-01       Impact factor: 6.860

2.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

Review 3.  The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.

Authors:  J E Talmadge; R B Herberman
Journal:  Cancer Treat Rep       Date:  1986-01

4.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

5.  The synergistic anti-proliferative effect of gamma-interferon and human lymphotoxin.

Authors:  S H Lee; B B Aggarwal; E Rinderknecht; F Assisi; H Chiu
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

6.  Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions.

Authors:  A Uchida; M Micksche
Journal:  Int J Cancer       Date:  1983-07-15       Impact factor: 7.396

7.  Lymphokine-activated killer cell and interleukin-2 inhibitors: their role in adoptive immunotherapy.

Authors:  A M Eggermont; P H Sugarbaker
Journal:  Cell Immunol       Date:  1987-07       Impact factor: 4.868

8.  Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.

Authors:  P H Sugarbaker; W Matthews; E P Steller; A M Eggermont
Journal:  J Biol Response Mod       Date:  1987-08

9.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

10.  Interleukin 2 promotes conjugate formation by purified LAK precursors and T lymphocytes: evaluation of conjugates using flow cytometric techniques.

Authors:  K Roberts; M T Lotze
Journal:  J Biol Response Mod       Date:  1988-06
View more
  2 in total

1.  Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

Authors:  Edmund Chiong; I-Ling Lee; Ali Dadbin; Anita L Sabichi; Loleta Harris; Diana Urbauer; David J McConkey; Rian J Dickstein; Tiewei Cheng; H Barton Grossman
Journal:  Clin Cancer Res       Date:  2011-03-17       Impact factor: 12.531

2.  Role of intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) in peripheral blood mononuclear cell activation by human renal carcinoma cells.

Authors:  A B Hansen; C B Andersen
Journal:  Urol Res       Date:  1994
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.